Although Amgen Inc.'s Phase III Vectibix-Folfox combination met its main goal - to improve progression-free survival in patients with advanced colorectal cancer in the first-line setting - it missed its secondary endpoint of overall survival, the company reported Thursday. (BioWorld Today) Read More
